Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384605 | 0.88 | PLA2G2A (0.42) | CA1CA2CA7CA9PLA2G10 | |
| SCHEMBL29026158 | 0.84 | L3MBTL1 (0.40) | CA1CA2CA7CA9PLA2G10 | |
| SCHEMBL11557514 | 0.83 | PLA2G10 (0.49) | ALDH1A1CNR1CNR2PLA2G10PLA2G2A | |
| SCHEMBL24207921 | 0.83 | L3MBTL1 (0.39) | CA1CA2CA7CA9PLA2G10 | |
| SCHEMBL29023378 | 0.83 | L3MBTL1 (0.39) | CA1CA2CA7CA9PLA2G10 | |
| SCHEMBL25260093 | 0.83 | L3MBTL1 (0.39) | CA1CA2CA7CA9PLA2G10 | |
| SCHEMBL25258443 | 0.83 | L3MBTL1 (0.39) | CA1CA2CA7CA9PLA2G10 | |
| SCHEMBL24339761 | 0.82 | PLA2G10 (0.51) | ALDH1A1CNR1CNR2PLA2G10PLA2G2A | |
| SCHEMBL24339548 | 0.82 | PLA2G10 (0.51) | ALDH1A1CNR1CNR2PLA2G10PLA2G2A | |
| SCHEMBL17202224 | 0.82 | PLA2G10 (0.51) | ALDH1A1CNR1CNR2PLA2G10PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| CN-102271517-A | oxidized lipid compounds and uses thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
| EP-2348866-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | Vascular Biogenics Ltd. (IL) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010052718-A9 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010052718-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | ALDH1A1 616/4885CNR1 2066/4885CNR2 1326/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | ALDH1A1 616/4885CNR1 2066/4885CNR2 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.